

Albert WÄJfler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3886131/publications.pdf>

Version: 2024-02-01

64
papers

1,792
citations

293460

24
h-index

325983

40
g-index

66
all docs

66
docs citations

66
times ranked

3189
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. <i>Annals of Hematology</i> , 2022, 101, 837-846.	0.8	5
2	Austrian recommendations for the management of essential thrombocythemia. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 52-61.	1.0	2
3	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. <i>Clinical Epigenetics</i> , 2021, 13, 1.	1.8	57
4	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. <i>Leukemia</i> , 2021, 35, 1521-1526.	3.3	3
5	Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio. <i>ESC Heart Failure</i> , 2021, 8, 3397-3402.	1.4	3
6	Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. <i>Lancet, The</i> , 2021, 397, 1842.	6.3	25
7	SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban. <i>Lancet, The</i> , 2021, 397, e19.	6.3	23
8	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. <i>Annals of Hematology</i> , 2021, 100, 2845-2847.	0.8	1
9	Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. <i>Stroke and Vascular Neurology</i> , 2021, , svn-2021-001142.	1.5	20
10	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. <i>Haematologica</i> , 2020, 105, 375-386.	1.7	11
11	The role of germline mutation profiling in the selection of related donors for haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1502-1505.	1.3	3
12	TNF α Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBP β . <i>Cells</i> , 2020, 9, 1223.	1.8	3
13	A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 415-422.	1.0	0
14	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. <i>American Journal of Hematology</i> , 2020, 95, 1148-1157.	2.0	13
15	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 496.	1.7	12
16	Feasibility and safety of using an automated decision support system for insulin therapy in the treatment of steroid-induced hyperglycemia in patients with acute graft-versus-host disease: A randomized trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 339-342.	1.1	8
17	Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1798.	2.2	19
18	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019, 10, 4666.	5.8	146

#	ARTICLE	IF	CITATIONS
19	High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34 ⁺ positive AML. <i>Cancer Medicine</i> , 2019, 8, 1771-1778.	1.3	22
20	Detection of AML-specific TP53 mutations in bone marrow ⁺ derived mesenchymal stromal cells cultured under hypoxia conditions. <i>Annals of Hematology</i> , 2019, 98, 2019-2020.	0.8	4
21	Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 516-523.	1.7	65
22	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K γ in Mature B-cell Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 1103-1113.	3.2	18
23	Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration. <i>Blood</i> , 2018, 131, 826-830.	0.6	10
24	Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	41
25	Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. <i>Leukemia and Lymphoma</i> , 2018, 59, 501-504.	0.6	41
26	The frequency of occurrence of fish-shaped red blood cells in different haematologic disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 323-326.	1.4	0
27	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 23-30.	2.0	16
28	Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. <i>Mycoses</i> , 2018, 61, 201-205.	1.8	27
29	Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. <i>Journal of Infection</i> , 2018, 77, 235-241.	1.7	78
30	Ruxolitinib therapy for myelofibrosis in Austria. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 495-504.	1.0	5
31	Austrian recommendations for the management of polycythemia vera. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 535-542.	1.0	3
32	Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. <i>Medical Mycology</i> , 2017, 55, myw102.	0.3	65
33	Red blood cell morphology in patients with β^2 -thalassemia minor. <i>Laboratoriums Medizin</i> , 2017, 41, 49-52.	0.1	2
34	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	0.6	44
35	Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <i>American Journal of Hematology</i> , 2017, 92, 885-891.	2.0	47
36	Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1186-1192.	2.0	13

#	ARTICLE	IF	CITATIONS
37	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 293-302.	1.0	6
38	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. <i>Blood Cancer Journal</i> , 2017, 7, 643.	2.8	11
39	Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. <i>Blood</i> , 2017, 130, 946-948.	0.6	52
40	Evidence for a role of decitabine in the treatment of myeloid sarcoma. <i>Annals of Hematology</i> , 2017, 96, 505-506.	0.8	20
41	Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2080.	1.8	58
42	Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP. <i>Cancer Research</i> , 2016, 76, 3644-3654.	0.4	45
43	Acute myeloid leukemia with TP53 germ line mutations. <i>Blood</i> , 2016, 128, 2270-2272.	0.6	39
44	Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis. <i>Leukemia Research</i> , 2016, 42, 47-51.	0.4	17
45	Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta-D-Glucan Levels?. <i>Journal of Clinical Microbiology</i> , 2016, 54, 798-801.	1.8	17
46	Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies. <i>Journal of Clinical Microbiology</i> , 2016, 54, 771-774.	1.8	20
47	Prognostic potential of 1,3-beta-d-glucan levels in bronchoalveolar lavage fluid samples. <i>Journal of Infection</i> , 2016, 72, 29-35.	1.7	16
48	Diagnostic accuracy of the <i>Aspergillus</i> -specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. <i>Mycoses</i> , 2015, 58, 461-469.	1.8	51
49	Adipose triglyceride lipase acts on neutrophil lipid droplets to regulate substrate availability for lipid mediator synthesis. <i>Journal of Leukocyte Biology</i> , 2015, 98, 837-850.	1.5	64
50	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. <i>Critical Care</i> , 2015, 19, 178.	2.5	65
51	Deletion of SPRY4 is a frequent event in secondary acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 1923-1924.	0.8	5
52	Detection of (1 \rightarrow 3)-D-glucan in same-day urine and serum samples obtained from patients with haematological malignancies. <i>Mycoses</i> , 2015, 58, 394-398.	1.8	13
53	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. <i>Nature Communications</i> , 2014, 5, 5191.	5.8	51
54	Serum and urine galactomannan testing for screening in patients with hematological malignancies. <i>Medical Mycology</i> , 2014, 52, 647-652.	0.3	21

#	ARTICLE	IF	CITATIONS
55	Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 140-144.	1.1	24
56	Myeloid sarcoma in the oral cavity. <i>International Journal of Stomatology & Occlusion Medicine</i> , 2013, 6, 65-69.	0.1	3
57	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 246-250.	1.7	46
58	Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. <i>Journal of Infection</i> , 2012, 65, 588-591.	1.7	66
59	Germline mutations in the DNA damage response genes <i>BRCA1</i> , <i>BRCA2</i> , <i>BARD1</i> and <i>TP53</i> in patients with therapy related myeloid neoplasms. <i>Journal of Medical Genetics</i> , 2012, 49, 422-428.	1.5	87
60	Lineage-instructive function of C/EBP β in multipotent hematopoietic cells and early thymic progenitors. <i>Blood</i> , 2010, 116, 4116-4125.	0.6	59
61	Site-Specific Ubiquitination Determines Lysosomal Sorting and Signal Attenuation of the Granulocyte Colony-Stimulating Factor Receptor. <i>Traffic</i> , 2009, 10, 1168-1179.	1.3	31
62	Lineage Instructive Function of C/EBP β in Multipotent Hematopoietic Progenitor Cells Revealed in a Novel Cebpa-Cre Knock-in Model. <i>Blood</i> , 2008, 112, 2458-2458.	0.6	0
63	Characterization of a Juxtamembrane Lysine as a Determinant in Lysosomal Routing and Signal Downregulation of the Activated G-CSF Receptor (G-CSFR).. <i>Blood</i> , 2007, 110, 2190-2190.	0.6	2
64	A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. <i>Blood</i> , 2005, 105, 3731-3736.	0.6	47